DENNIS LEBBIN, M.D.; WILL G. RYAN, M.D., F.A.C.P.; THEODORE B. SCHWARTZ, M.D., F.A.C.P.
Mithramycin is a cytotoxic antibiotic that causes hypocalcemia and diminishes the elevated osteoclastic activity characteristic of Paget's disease. Previous inpatient studies have shown that this drug causes striking clinical and biochemical improvement in patients with severe widespread disease. To simplify therapy and lessen toxicity, 13 patients with this form of Paget's disease were treated for 1 to 14 months with either of two different outpatient regimens. During therapy the elevation in the serum alkaline phosphatase decreased by 40% to 99%, and all patients reported symptomatic improvement. Manifestations of toxicity were mild and transient.
LEBBIN D, RYAN WG, SCHWARTZ TB. Outpatient Treatment of Paget's Disease of Bone with Mithramycin. Ann Intern Med. ;81:635–637. doi: 10.7326/0003-4819-81-5-635
Download citation file:
Published: Ann Intern Med. 1974;81(5):635-637.
Emergency Medicine, Endocrine and Metabolism, Fluid and Electrolyte Disorders, Nephrology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use